NCT03733834|UnknownDMC
SD vs. NSD Therapy in Elderly AML
Comparisiom of Standard (SD) Therapy and Non-standard (NSD) Therapy in Elderly Acute Myeloid Leukemia (AML)
Loading search results
Comparisiom of Standard (SD) Therapy and Non-standard (NSD) Therapy in Elderly Acute Myeloid Leukemia (AML)
Sponsor study identifier
observational
1,000
1 country
1
Study Start
October 8, 2018
Actual (reported)Primary Completion
September 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
It is known that treatment outcome could be positively associated with treatment intensity. However, tolerance of chemotherapy decreases in the elder, some patients could not tolerate standard (SD) therapy and even died of side effect, and overall survival (OS) might not be prolonged. Whether all elder acute myeloid leukemia (AML) patients could benefit from SD therapy, or some should receive reduced-intensity therapy or even only supporting care remains controvertal. In this multi-center study, we are going to evaluate the benefit of SD and non-SD (NSD) therapy in elder AML patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 8, 2018
Actual (reported)November 6, 2018
Actual (reported)November 7, 2018
Actual (reported)September 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Overall survival
The time from AML diagnosis to patients death or last folloeing-up.
2 years
Relapse-free survival
2 years
Relapse incidence
2 years
Treatment-related mortality
1 year
SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
Newly diagnosed AML exclusive of APL with age range from 60 years old to 75 ages old. Patients are expect to live longger than 3 months.
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
Qifa Liu
Nanfang Hospital, Southern Medical University
First Submitted
November 6, 2018
First Posted
November 7, 2018
Study Start
October 8, 2018
Actual (reported)Primary Completion
September 2020
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
November 7, 2018
Record last verified: 2018-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: